First In Class News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from First in class. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In First In Class Today - Breaking & Trending Today

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held 28 September 2023 at 8:00 AM EST (10:00 PM AEST). Please click on the link to watch the replay: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 29, 2023 /PRNewswire/ Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced pos ....

San Diego , United States , United Kingdom , University Of California San Diego , South Australia , Spyros Papapetropoulos , Murrayb Stein , Prnewswire Bionomics Limited Nasdaq , Merck Co Inc , Affairs San Diego Healthcare System , Bionomics Or Company , Public Health , Drug Administration , Montgomery Sberg Depression Rating Scale , Insomnia Severity Index , Sheehan Disability Scale , Distinguished Professor , California San Diego , Staff Psychiatrist , Veteran Affairs San Diego Healthcare System , Hamilton Anxiety Rating Scale , Montgomery Asberg Depression Rating Scale , Clinician Global Impression , Patient Global Impression , Traumatic Stress Disorder , Social Anxiety Disorder ,

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Moitreyee Chatterjee Kishore , Naoki Okamura , Oncology Development , Astellas Pharma Inc , European Commission , Committee For Medicinal Products Human Use , European Medicines Agency , Senior Vice President , Immuno Oncology Development , Medicinal Products , Human Use , Press Release Image , First In Class , Ldn182 Targeted , First Line , Her2 Negative , Press Release , Ews Release ,

$1.1 Trillion Was Invested In The Transition To Clean Energy In 2022 This Company Reports Capitalizing On The Trend With Its First-In-Class Thematic ...

Thematic exchange-traded funds (ETFs) take advantage of long-term market trends , and the portfolios for these funds are often involved in industry- ....

Its Energy Transition Materials , Sprott Inc , Energy Transition Materials , Sprott Asset Management , Asset Management , Pure Play Thematic , Lithium Miners , Junior Copper Miners , Uranium Miners , Junior Uranium Miners , Nickel Miners , First In Class ,

Astellas Submits New Drug Application for Zolbetuximab in Japan

Astellas Submits New Drug Application for Zolbetuximab in Japan
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Pranob Bhattacharya , Naoki Okamura , Ministry Of Health , Astellas Pharma Inc , Oncology Development , Drug Application To Japan Ministry Of Health , Japan Ministry Of Health , Astellas Submits New Drug Application , New Drug Application , Executive Director , Interim Head , Immuno Oncology Development , Press Release Image , First In Class , Ldn182 Targeted , First Line , Her2 Negative , Press Release , Ews Release ,

China's Junshi Grants UK Hikma Exclusive Rights to Market New Cancer Drug in Middle East, North Africa

China's Junshi Grants UK Hikma Exclusive Rights to Market New Cancer Drug in Middle East, North Africa
yicaiglobal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yicaiglobal.com Daily Mail and Mail on Sunday newspapers.

Futura Costaglione , Junshi Biosciences , Hikma Mena , United Kingdom Hikma Pharmaceuticals , Yicai Global , Middle East , United Arab Emirates Based Hikma Mena , Southeast Asia , Exclusive Rights , Developing And Commercial Rights , Regional Rights , North African , First In Class , Cancer Treatment , Hikma Pharmaceuticals ,